Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

Groundbreaking single-dose vaccine found effective in preventing HIV - Strategy may lead to new vaccines that only need to be ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

On May 30, a team of researchers funded by the National Institutes of Health got the word: Funding for their vaccine ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

In the quest to develop an effective HIV vaccine, scientists from Scripps Research have made a significant leap forward. They ...

According to a phase 1 trial, the experimental HIVconsvX vaccine is safe and immunogenic among sub-Saharan African ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

Health authorities in Zambia have halted a planned clinical trial for an HIV vaccine after the United States withdrew funding ...

The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...